MedTrace Logo

Treatment of RP and LCA by Primary RPE Transplantation

NCT03566147 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-08-09

No results posted yet for this study

Summary

Early Phase I Study of the Safety and Preliminary Efficacy of Human primary Retinal Pigment Epithelial (HuRPE) Cells Subretinal Transplantation in Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA) Patients

Conditions

  • Leber Congenital Amaurosis, Retinitis Pigmentosa

Interventions

BIOLOGICAL

Human primary Retinal Pigment Epithelial (HuRPE) cells

HuRPE will be transplanted by a board-certified vitreoretinal surgeon, which will be administered into the subretinal space of experimental eye through a standard surgical approach.

Sponsors & Collaborators

  • Beijing Tongren Hospital

    collaborator OTHER

  • Eyecure Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Ningli Wang · Beijing Tongren Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-01
Primary Completion
2019-12-31
Completion
2020-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03566147 on ClinicalTrials.gov